Abstract
In 47 children with malignancy, zinc status, growth, and performance during standard treatment were compared with those in controls. At diagnosis, growth was retarded and hair zinc values were high, 2.4±0.7 μmol/g, as in chronic deficiency. During induction therapy, serum declined to 10.4±2.3 μmol/L and urinary excretion increased to 5.3±2.8 μmol/mol creatinine, as in acute exacerbation of deficiency. Control CSF values in children in remission, 0.04±0.01 μmol/L, were lower than reference values in adults. No difference in mean CSF zinc was observed during therapy, or in those with acute lymphoblastic leukemia (1) at high risk, (2) with central nervous system involvement, (3) with low performance, or (4) resistant to therapy. In six children unexplained values, up to 0.28 μmol/L during induction, were measured. No correlations between the various zinc parameters were found.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
A. O. Çavdar, E. Babacan, S. Gözdaşoglu, J. Erten, S. Cin, A. Arcasoy, and U. Ertem,Cancer 59, 305–309 (1987).
J. B. Sengas, P. D. Goumas, N. Papadimatos, and E. S. HelidonisMed. Sci. Res. 15, 793–794 (1987).
A. Joseph, S. Apelgot, and E. GuilleAnticancer Res. 7, 833–838 (1987).
E. A. Cutler, J. Palmer, S. B. KontrasN. Engl. J. Med. 297, 168–169 (1977).
U. Lasson, K. Dörner, and G. MauDtsch. Med. Wochenschr. 104, 1283 (1979).
H. T. Delves, F. W. Alexander, and H. LayBr. J. Haematol. 24, 525–531 (1973).
K. Saito, T. Saito, T. Hosokawa, S. Fujimoto, and T. SasakiTrace Elem. Med. 1, 24–28 (1984).
Y. Beguin, G. Weber, J. M. Delbroeck, I. Roelandts, G. Robaye, J. Bury, and G. FilletActa Pharm. Toxicol. 59, (Suppl VII), 270–273 (1986).
P. A. Walravens, N. F. Krebs, and K. M. HambidgeAm. J. Clin. Nutr. 38, 195–201 (1983).
C. J. FredericksonInt. Rev. Neurobiol. 31, 215–220 (1989).
J. C. Van Wieringen, M. J. Roede, and J. M. WitTijdschr. Kindergeneeskd. 53, 147–152 (1985).
K. E. C. De Haan, C. J. De Groot, C. J. A. Van den Hamer, and H. BoxmaClin. Chim. Acta. 170, 111–112 (1987).
H. J. De Groot, E. J. M. De Haase, P. D'Haese, A. Heyndrickx, and F. A. De WolffPharm. Weekbl. [Sci.] 6, 11–15 (1984).
A. J. HartzArch. Pathol. Lab. Med. 108, 65–67 (1984).
J. P. Van Wouwe, H. H. Van Gelderen, and J. H. BosEur. J. Pediatr. 146, 293–295 (1986).
J. P. Van Wouwe, H. H. Van Gelderen, F. A. J. Enschedé, and E. A. Van de VeldeTrace Elem. Med. 5, 90–92 (1988).
K. E. C. De Haan, J. J. M. De Goeij, G. J. De Groot, and C. J. A. Van den Hamer (Submitted.)
J. P. Van Wouwe, M. Veldhuizen, J. J. M. De Goeij, and C. J. A. Van den HamerPediatr. Res. 28, 332–335 (1990).
A. El-Yazigi, I. Al-Saleh, and O. Al-MeftyClin. Chem. 32, 2187–2190 (1986).
V. IyengarSci. Total. Environ. 71, 1–5 (1988).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Van Wouwe, J.P., van Zuylen, L. Changes of zinc values in children during malignant disease. Biol Trace Elem Res 30, 197–204 (1991). https://doi.org/10.1007/BF02991414
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02991414